Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (351-360 of 457) with videos related to

Pageof 46
Sort By:
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid LeukemiaGege Gui, Laura W Dillon, Niveditha Ravindra, et al.
British Journal of Haematology|December 11, 2002
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remissionMark R Litzow, Waleska S Pérez, John P Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Acta Haematologica|June 8, 2026
Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignanciesMaymona Abdelgamid, Naima J Hashi, Mehrdad Hefazi, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
American Journal of Hematology|December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patientsNaseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
Blood Advances|March 21, 2019
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cellsYi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, et al.
Blood|December 25, 2009
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemiaMark R Litzow, Sergey Tarima, Waleska S Pérez, et al.
American Journal of Hematology|December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survivalOmer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Pageof 46

Showing results (351-360 of 457) with videos related to

Sort By:
Pageof 46
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid LeukemiaGege Gui, Laura W Dillon, Niveditha Ravindra, et al.
British Journal of Haematology|December 11, 2002
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remissionMark R Litzow, Waleska S Pérez, John P Klein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Acta Haematologica|June 8, 2026
Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignanciesMaymona Abdelgamid, Naima J Hashi, Mehrdad Hefazi, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
American Journal of Hematology|December 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patientsNaseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
Blood Advances|March 21, 2019
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cellsYi-Bin Chen, Jennifer Le-Rademacher, Ruta Brazauskas, et al.
Blood|December 25, 2009
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemiaMark R Litzow, Sergey Tarima, Waleska S Pérez, et al.
American Journal of Hematology|December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survivalOmer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Pageof 46